Nicox S.A. (NICXF)
USD 0.24
(0.0%)
USD 0.24
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -11.5 Million EUR | -35.28% |
| 2022 | -8.5 Million USD | 66.27% |
| 2021 | -25.21 Million USD | -284.56% |
| 2020 | 13.65 Million USD | 107.17% |
| 2019 | 6.59 Million USD | 63.73% |
| 2018 | 4.02 Million EUR | 74.71% |
| 2017 | 2.3 Million EUR | 118.02% |
| 2016 | -12.79 Million EUR | -144.15% |
| 2015 | -5.23 Million EUR | -294.76% |
| 2014 | 2.69 Million EUR | 2179.66% |
| 2013 | 118 Thousand EUR | -98.45% |
| 2012 | 7.6 Million EUR | 0.0% |
| 2011 | - EUR | -100.0% |
| 2010 | 7.42 Million EUR | 611.02% |
| 2009 | 1.04 Million EUR | -60.03% |
| 2008 | 2.61 Million EUR | -85.86% |
| 2007 | 18.46 Million EUR | 130.14% |
| 2006 | 8.02 Million EUR | 68.84% |
| 2005 | 4.75 Million EUR | 551.81% |
| 2004 | -1.05 Million EUR | -174.93% |
| 2003 | 1.4 Million EUR | -74.32% |
| 2002 | 5.46 Million EUR | 0.0% |
| 2001 | - EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 FY | -11.5 Million EUR | -35.28% |
| 2023 Q2 | 1.62 Million USD | 160.55% |
| 2023 Q1 | -2.68 Million EUR | -305.38% |
| 2022 Q1 | -3.51 Million EUR | 84.53% |
| 2022 Q2 | -9.25 Million USD | -163.54% |
| 2022 Q3 | -4.1 Million EUR | 55.67% |
| 2022 Q4 | 1.3 Million USD | 131.91% |
| 2022 FY | -8.5 Million USD | 66.27% |
| 2021 Q2 | 513 Thousand EUR | 110.09% |
| 2021 Q3 | -1.15 Million EUR | -325.66% |
| 2021 Q4 | -22.7 Million EUR | -1860.98% |
| 2021 FY | -25.21 Million USD | -284.56% |
| 2021 Q1 | -5.08 Million EUR | -152.6% |
| 2020 FY | 13.65 Million USD | 107.17% |
| 2020 Q4 | 9.67 Million EUR | 280.73% |
| 2020 Q3 | 2.53 Million EUR | 70.0% |
| 2020 Q1 | -2.28 Million EUR | -757.59% |
| 2020 Q2 | 1.49 Million EUR | 165.29% |
| 2019 FY | 6.59 Million USD | 63.73% |
| 2019 Q4 | 347.99 Thousand EUR | 107.14% |
| 2019 Q3 | -4.87 Million EUR | -339.84% |
| 2019 Q1 | -1.09 Million EUR | 71.89% |
| 2019 Q2 | -1.1 Million EUR | -1.38% |
| 2018 Q3 | -3.94 Million EUR | -22.35% |
| 2018 Q2 | -3.22 Million EUR | 5.21% |
| 2018 FY | 4.02 Million EUR | 74.71% |
| 2018 Q4 | -3.88 Million EUR | 1.32% |
| 2018 Q1 | -3.39 Million EUR | 0.0% |
| 2017 Q1 | -2.71 Million EUR | 57.56% |
| 2017 Q2 | -2.9 Million EUR | -7.06% |
| 2017 FY | 2.3 Million EUR | 118.02% |
| 2016 Q4 | -6.39 Million EUR | 6.3% |
| 2016 Q2 | 4997.50 EUR | -2.49% |
| 2016 Q1 | 5124.99 EUR | 162.92% |
| 2016 Q3 | -6.83 Million EUR | -136770.37% |
| 2016 FY | -12.79 Million EUR | -144.15% |
| 2015 Q4 | -8145.53 EUR | 2.68% |
| 2015 FY | -5.23 Million EUR | -294.76% |
| 2015 Q3 | -8370.07 EUR | -119.27% |
| 2015 Q2 | 43.44 Thousand EUR | 3.69% |
| 2015 Q1 | 41.89 Thousand EUR | 0.0% |
| 2014 FY | 2.69 Million EUR | 2179.66% |
| 2014 Q2 | 301.86 Thousand EUR | -0.64% |
| 2014 Q1 | 303.82 Thousand EUR | 12.11% |
| 2013 Q4 | 271 Thousand EUR | 676.6% |
| 2013 FY | 118 Thousand EUR | -98.45% |
| 2013 Q3 | -47 Thousand EUR | -104.35% |
| 2013 Q2 | -23 Thousand EUR | -35.29% |
| 2013 Q1 | -17 Thousand EUR | -147.22% |
| 2012 FY | 7.6 Million EUR | 0.0% |
| 2012 Q3 | 19 Thousand EUR | -70.77% |
| 2012 Q4 | 36 Thousand EUR | 89.47% |
| 2012 Q1 | 7.48 Million EUR | 0.0% |
| 2012 Q2 | 65 Thousand EUR | -99.13% |
| 2011 FY | - EUR | -100.0% |
| 2011 Q3 | - EUR | 0.0% |
| 2011 Q1 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2010 Q3 | - EUR | 0.0% |
| 2010 Q1 | 7.42 Million EUR | 0.0% |
| 2010 FY | 7.42 Million EUR | 611.02% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q2 | - EUR | -100.0% |
| 2009 Q1 | 341 Thousand EUR | 0.0% |
| 2009 FY | 1.04 Million EUR | -60.03% |
| 2008 FY | 2.61 Million EUR | -85.86% |
| 2007 FY | 18.46 Million EUR | 130.14% |
| 2006 FY | 8.02 Million EUR | 68.84% |
| 2005 FY | 4.75 Million EUR | 551.81% |
| 2004 FY | -1.05 Million EUR | -174.93% |
| 2003 FY | 1.4 Million EUR | -74.32% |
| 2002 FY | 5.46 Million EUR | 0.0% |
| 2001 FY | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 176.692% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 370925.274% |
| SQZ Biotechnologies Company | 9.79 Million USD | 217.449% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 198.266% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 109.658% |
| Mesoblast Limited | -35.16 Million USD | 67.291% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -33583.748% |
| Genus plc | 178.7 Million USD | 106.437% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 2904.481% |
| Marizyme, Inc. | 457.7 Thousand USD | 2613.207% |
| ContraFect Corporation | -154 Thousand USD | -7369.481% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -104472.727% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -22906.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 15085.474% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 17600.913% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -2868.508% |
| MultiCell Technologies, Inc. | 49.32 USD | 23323295.458% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 128.568% |
| EV Biologics, Inc. | 48.9 Thousand USD | 23623.517% |
| Q BioMed Inc. | -8988.00 USD | -127881.753% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 140.711% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -74478.579% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 105.226% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 16532.857% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -9157.873% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 18585.842% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -232189.984% |
| Arch Therapeutics, Inc. | -2439.00 USD | -471527.716% |
| IMV Inc. | -962.29 Thousand USD | -1095.368% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 8287.189% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -11696.134% |
| GB Sciences, Inc. | -624.00 USD | -1843329.487% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -13271.228% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.152% |
| Halberd Corporation | -208.00 USD | -5530188.462% |
| Enzolytics Inc. | 30.7 Thousand USD | 37559.294% |
| Resverlogix Corp. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 947.589% |
| SYBLEU INC | 11.69 Thousand USD | 98449.863% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 2484.373% |
| argenx SE | 1.1 Billion USD | 101.038% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 55.411% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 1963.184% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 102.809% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -129789.341% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 125.932% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -907.646% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 1264.294% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 219.686% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -13618.709% |
| BioStem Technologies, Inc. | 15.42 Million USD | 174.574% |
| ONE Bio Corp. | 20.12 Million USD | 157.157% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -97094.761% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -23735.968% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 6615.066% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 6615.066% |
| NovAccess Global Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -2135.719% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | -1725.473% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -39565.517% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 2655.978% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -3500.234% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 349.631% |
| Bioxytran, Inc. | -8285.00 USD | -138741.279% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -2983.914% |
| Neutra Corp. | 14.33 Thousand USD | 80344.158% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -13928.049% |
| PureTech Health plc | -1.6 Million USD | -617.592% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -1048.88% |
| IXICO plc | 3.27 Million USD | 451.774% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -1557.493% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -542.267% |
| CSL Limited | 7.7 Billion USD | 100.149% |
| Cellectis S.A. | 18 Thousand USD | 64005.556% |